

Xtampza ER[®] Long-Acting Opioid Prior Authorization Request Form (Page 1 of 3)

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NPI#:		Specialty:	
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City: State: Zip:			Office Street Address:			
Phone:			City:	State:	Zip:	
Medication Information (required)						
Medication Name:		Strength:		Dosage Form:		
Check if requesting brand			Directions for Use:			
Check if request is for continuation of therapy						
		Clinical Inform	nation (required)			
For states, such as AR following:	, that have a terminal i	llness mandate, and fo	r patients who have a	terminal illn	ess, please answer the	
Will the requested medic If " YES ", please indicate				nptoms? [❑ Yes ❑ No months (please specify)	
Please answer the follo	· · · · · · · · · · · · · · · · · · ·					
Is the patient currently established on the requested long-acting opioid? Yes No						
	,	nced by coverage effecti	ve date of less than or e	equal to 120	days)? 🛛 Yes 🗆 No Select all	
the applicable diagnos Cancer or end of life r						
Moderate to severe ch	nronic pain that is non-ne					
 Moderate to severe ne Other diagnosis: 	europathic pain or fibron	nyalgia (examples of neu	iropathic pain include ne	euralgias, nei	uropathies)	
For diagnosis of cance	er or end of life (defined	d as a < 2 years life exp	ectancy) related pain,	please ans	wer the following:	
Does the patient have an active cancer diagnosis or life expectancy of < 2 years? Yes No						
Will medical records documenting an active cancer diagnosis or life expectancy of < 2 years be submitted to <i>ProAct[®]</i> with this fax form?					$ProAct^{\circ}$ with this fax form?	
***Please note: Medical records documenting an active cancer diagnosis or li			or life expectancy of <	2 years is ree	quired to be submitted along	
with this fax form. ***						
For diagnosis of moderate to severe chronic pain that is non-neuropathic, please answer the following:						
Is the requested medication being used as an as-needed (PRN) analgesic? I Yes I No						
Is the requested medication being used for pain that is mild or not expected to persist for an extended period of time? Yes No Is the requested medication being used for acute pain? Yes No						
Is the requested medication being used for postoperative pain? The Yes I No If yes, please answer the following:						
 Has the patient already received chronic opioid therapy prior to surgery or is the postoperative pain expected to be moderate to severe and persist for an extended period of time? Yes No 						
Prior to the start of therapy with the requested long-acting opioid, has the patient failed an adequate trial of a short-acting opioid? 🗆 Yes 🗆 No						
If yes, please document the name of the medication(s), date, and duration of trial: Medication: Date of trial: Duration:				of trial:		

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: XtampzaER_Comm_2017Sep-W



1230 US Highway 11

Gouverneur, NY 13642

Phone: 1-877-635-9545

Prior Authorization Fax: 1-844-712-8129

Xtampza ER[®] Long-Acting Opioid Prior Authorization Request Form (Page 2 of 3)

For diagnosis of moderate to severe neuropathic pain or fibromyalgia, please answer the following: Does the patient have a contraindication to or has not exhibited an adequate response to treatment with gabapentin titrated to a therapeutic dose? U Yes U No If yes, please document dose, date, and duration of trial Dose: Date of trial: Duration of trial:						
Does the patient have a contraindication to or has not exhibited an adequate response to treatment with a tricyclic antidepressant titrated to the maximum tolerated dose? Yes No If yes, please document drug, dose, date, and duration of trial: Medication:Dose:Date of trial:Duration of trial:						
Clinical information [Non-cancer and non-end of life pain only]:						
 What are the treatment goals for this patient? (Document treatment goals) 	_					
 What alternative nonopioid analgesic and/or nonpharmacologic interventions are currently being used with this requested medication? (Document other treatment interventions) 						
3. Has the patient demonstrated meaningful improvement in pain scale score? (Document score) Yes No	_					
What is the patient's most recent score on a substance abuse/opioid dependence risk assessment tool? (Document score)						
5. What is the rationale for not tapering and discontinuing the requested medication? (Document rationale)						
 What comorbid mental health conditions has the patient been screened for? (Document mental health conditions for which the patient has been screened) 						
 Has the state's prescription drug monitoring program (PDMP) been reviewed for this patient? Yes	_					
8. Has the patient been assessed for risk of respiratory depression from medical comorbidities or the concurrent use of benzodiazepines or other drugs causing drug-drug interactions and the prescriber acknowledges that they have completed an assessment of increased risk for respiratory depression? Yes No						
9. What is the patient's total daily dose?	_					
Select the medications the patient has a history of failure, contraindication, or intolerance to:						
Embeda (morphine sulfate and naltrexone hydrochloride) Oxycontin (oxycodone hydrochloride)						
 Hydromorphone extended-release (ER) Morphine sulfate ER Oxymorphone ER 						

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: XtampzaER_Comm_2017Sep-W



1230 US Highway 11

Gouverneur, NY 13642

Phone: 1-877-635-9545

Prior Authorization Fax: 1-844-712-8129

Xtampza ER[®] Long-Acting Opioid Prior Authorization Request Form (Page 3 of 3)

Quantity limit requests:

What is the quantity requested perDAY?

For diagnosis of cancer related pain or who are end of life (life expectancy < 2 years), please answer the following:

Can the requested dose be achieved by moving to a higher strength dosage form?
Yes No

For diagnosis of non-cancer or non-end of life related pain, please answer the following:

Does the requested dose exceed 90 morphine equivalent doses (MED) daily? □ Yes □ No

Example of 90 MED equivalent: Xtampza ER = 54mg/day

What is the reason for exceeding the plan limitations?

□ Titration or loading-dose purposes

□ Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

- Requested strength/dose is not commercially available
- Other:

Prescriber attestation:

Does the prescriber attest that the information provided is true and accurate to the best of their knowledge and understand that ProAct may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided? 🗆 Yes 🗅 No Date:

Prescriber's signature:

Please note: All information must be completed and chart documentation (i.e., chart notes) [w here applicable] must be submitted to ProAct.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.

Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.

Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Re	presentative	(and Title)	
FIOVILIEI/RE	presentative	(and rule)	•

Date:

PROACT INTERNAL USE ONLY:						
Clinical Review Decision						
	Approved, through					
	Denied (documentation attached, if necessary)					
Tracking:						
1 st Attemp	ot		2 nd Attempt		Letter Mailed:	

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: XtampzaER_Comm_2017Sep-W